Why the study?
This study aimed to explore the diagnostic value of changes in high-sensitivity cardiac troponin I levels in patients with suspected NSTEMI.
Does a machine learning model using hs-cTnI 1-2h changes accurately distinguish NSTEMI from unstable angina in patients with chest pain?
Does a machine learning model using hs-cTnI 1-2h changes accurately distinguish NSTEMI from unstable angina in patients with chest pain?
A machine learning model incorporating hs-cTnI measurements at admission and 1-2 hours post-admission accurately distinguishes NSTEMI from unstable angina.
May aid early NSTEMI vs UA differentiation via hs-cTnI ML models; leaves open prospective validation before clinical use.
BACKGROUND: This study demonstrates differences in the distribution of multiple cardiovascular biomarkers between non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina (UA) patients. Diagnostic machine learning predictive models measured at the time of admission and 1/2 h post-admission, achieving competitive diagnostic predictive results. OBJECTIVE: This study aims to explore the diagnostic value of changes in high-sensitivity cardiac troponin I (hs-cTnI) levels in patients with suspected NSTEMI. METHODS: A total of 267 patients presented with chest pain, requiring confirmation of acute coronary syndrome (ACS) subtypes (NSTEMI vs. UA). Hs-cTnI and other cardiac markers, such as creatine kinase-MB (CK-MB) and Myoglobin (Myo), were analyzed. Machine learning techniques were employed to assess the application of hs-cTnI level changes in the clinical diagnosis of NSTEMI. RESULTS: < 0.001). There was a positive correlation between hs-cTnI and CK-MB, as well as Myo (R = 0.72, R = 0.51, R = 0.60). The optimal diagnostic model, Hybiome_1/2h, demonstrated an F1-Score of 0.74, an AUROC of 0.96, and an AP of 0.89. CONCLUSIONS: This study confirms the significant value of hs-cTnI as a sensitive marker of myocardial injury in the diagnosis of NSTEMI. Continuous monitoring of hs-cTnI levels enhances the accuracy of distinguishing NSTEMI from UA. The models indicate that the Hybiome hs-cTnI assays perform comparably well to the Beckman assays in predicting NSTEMI. Moreover, incorporating hs-cTnI measurements taken 1-2 h post-admission significantly enhances the model's effectiveness.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: